Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has announced the execution of a term sheet with arm's-length institutional investors for a previously announced non-brokered private placement. The offering is expected to raise approximately CAD$5 million through the issuance of 6,764,070 units at a notional price of CAD$0.7392 per unit. Each unit consists of one common share and one common share purchase warrant. The transaction is anticipated to close on or about July 15, 2026, subject to customary conditions and regulatory approvals.
Proceeds from the financing are intended to support the development of the company's ONC010 program, including manufacturing and preclinical testing activities, as well as the advancement of its SynoGraph(TM) platform and general working capital. Under the proposed structure, the company's economic interest will be determined through 18 monthly settlement tranches based on the future trading price of its shares, with additional details to be provided upon closing. This innovative financing mechanism reflects the company's strategic approach to funding its oncology research initiatives.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. It has secured an exclusive worldwide license to patented technology that targets solid tumors. The private placement represents a significant milestone for the company, providing the necessary capital to advance its pipeline and platform technologies.
For more information, the full press release is available at https://ibn.fm/y3hsM. The latest news and updates relating to ONNVF are available in the company's newsroom at https://ibn.fm/ONNVF.
